Table 3.

TXNIP expression in cancers of the respiratory system and others.

Tumor type	Upstream or downstream molecular	Significance	TXNIP expression	Samples	References
Lung cancer	PI3K/Akt	(TKIS) inhibits PI3K/Akt signaling in NSCLC's cell lines to increase the expression of TXNIP	Down	Cell lines	(98)
Lung cancer	ASK1	The drug combination can kill mutant non-small cell lung cancer	Down	Cell lines, tissue	(99)
Lung cancer	WDR5	TXNIP increase WDR5 expression to increase lung cell death	Down	Cell lines	(100)
Lung cancer	TRAF6	TXNIP can interact with TRAF6 to affect NSCLC's migration and proliferation	Down	Cell lines	(101)
Lung cancer	miR-411-5p/3p	Overexpression of miR-411-5p/3p can inhibit the expression of SPRY4 and TXNIP to promotes tumor's proliferation and migration	Down	Cell lines, tissue	(102)
Leukemia	ChREBP	ChREBP promotes the development of ROS to promote the occurrence and development of AML	Down	Cell lines, tissue	(103)
Leukemia	JQ1	JQ1 can reduce the expression of myc to activate the ASK1-MAPK pathway, which leads to the death of AML cells	Down	Cell lines, tissue, animal	(104)
Osteosarcoma	PRMT5	PRMT5 overexpression might confer resistance to chemotherapy	Down	Cell lines, tissue	(105)
Neuroblastoma	ROS	Fenofibrate inhibited proliferation and migration of NB cells by increasing intracellular ROS and up-regulating TXNIP expression	Down	Cell lines, tissue	(106)

PI3K, Phosphatidylinositide 3-kinases; Akt-protein kinaseB(PKB); TKIS, tyrosine kinase inhibitors; ASK1, Apoptosis signal-regulating kinase 1; TRAF6-TNF, receptor associated factor 6; JQ1, an Inhibitor of BET bromodomain; PRMT5, protein arginine methyltransferase 5.